Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880517 | 0.90 | MAPT (0.47) | GAANPSR1L3MBTL1MAPTTHRB | |
| SCHEMBL1887533 | 0.88 | MAPK8 (0.50) | GAANPSR1L3MBTL1MAPTTHRB | |
| SCHEMBL1887819 | 0.87 | NOTUM (0.51) | GAATSHRKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1889109 | 0.84 | MAPT (0.43) | GAANPSR1L3MBTL1MAPTTHRB | |
| SCHEMBL12672070 | 0.84 | GAA (0.44) | GAANPSR1L3MBTL1MAPTTHRB | |
| SCHEMBL1875614 | 0.84 | GAA (0.60) | GAANPSR1L3MBTL1MAPTTHRB | |
| SCHEMBL1877442 | 0.84 | MAPT (0.49) | GAANPSR1L3MBTL1MAPTTHRB | |
| SCHEMBL1880402 | 0.79 | MAPT (0.46) | GAANPSR1L3MBTL1MAPTTHRB | |
| SCHEMBL1884680 | 0.76 | NOTUM (0.51) | GAANPSR1TSHRKDM4EKMT2A | |
| SCHEMBL1882299 | 0.75 | TSHR (0.55) | GAANPSR1L3MBTL1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | ALLERGAN, INC. (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | S1PR1, S1PR2, S1PR3 | GAA 1804/4885NPSR1 37/4885L3MBTL1 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.